AstraZeneca PLC has come on board as a new big pharma partner to help the University of Oxford realise its hugely ambitious plans to have its COVID-19 vaccine ready by September.
Biotech Behind Oxford’s Coronavirus Vaccine Welcomes AZ’s Big Pharma 'Muscle'
Vaccitech Hails Partner's ‘Aggressive’ Trial Design
The University of Oxford spin-out is backing its academic partners to succeed against COVID-19 – but must also look to its own commercial future using the same adenovirus platform.
More from Business
More from Scrip
• By
European pharma leaders want to see a deal so that no tariffs are imposed on medicines – but they also want the European Union to urgently rethink its sector policies that they believe will lead to massive investment loss.
• By
The US president's most recent comments suggest tariffs on pharma are imminent and Ireland has the most to lose.
• By
Chinese biopharma companies’ alliance strategies are transitioning from immediate cash needs to more strategic management of portfolios, as MNCs continue to hunt for derisked assets.